(Q38166661)

30 August 2017

title

Effect of treating psoriasis on cardiovascular co-morbidities: focus on TNF inhibitors (English)

1 reference

30 August 2017

0 references

Jashin J Wu

3

0 references

author name string

Shannon Famenini

series ordinal

1

1 reference

30 August 2017

Eric Y Sako

series ordinal

2

1 reference

30 August 2017

publication date

1 February 2014

1 reference

American Journal of Clinical Dermatology

30 August 2017

published in

1 reference

30 August 2017

volume

15

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

45-50

1 reference

Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

The association of psoriasis and elevated blood lipids in overweight and obese children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Psoriasis may not be an independent predictor for the use of cardiovascular and anti-diabetic drugs: a 5-year prevalence study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Psoriasis and risk of cardiovascular disease: a meta-analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Anti-TNF-alpha-adalimumab therapy is associated with persistent improvement of endothelial function without progression of carotid intima-media wall thickness in patients with rheumatoid arthritis refractory to conventional therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Tumor necrosis factor inhibitors and myocardial infarction in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Association of ethnicity, tumor necrosis factor inhibitor therapy, and myocardial infarction risk in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Oxidative stress and psoriasis: the effect of antitumour necrosis factor-α inhibitor treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Paraoxonase 1 (PON1) 55 polymorphism, lipid profiles and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Novel and conventional biomarkers for prediction of incident cardiovascular events in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Psoriasis and new-onset diabetes: a Danish nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Serum leptin levels, skin leptin and leptin receptor expression in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

The role of tumor necrosis factor-α and TNF-α receptors in cerebral arteries following cerebral ischemia in rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumor necrosis factor-α blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40257-013-0052-6

10.1007/S40257-013-0052-6

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1006019566

0 references

1 reference